Sprint Bioscience Raises Funding
Published On November 25, 2010 |
Sprint Bioscience, a Stockholm, Sweden-based company focusing on early cancer drug discovery using fragment-based methods, has raised start up capital from ALMI Invest and Entreprenörsfonden.
Sprint Bioscience offers a platform for fragment-based drug discovery comprising protein expression and purification, fragment screening, high-throughput X-ray crystallography and full expansion of fragments into a patented lead series.
The company, which was founded in 2009 by Prof. Pär Nordlund and Dr. Anders Åberg,to large and small pharmaceutical companies.